Literature DB >> 12001123

Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.

Dage Liu1, Cheng-long Huang, Kotaro Kameyama, Eiichi Hayashi, Akira Yamauchi, Shinichi Sumitomo, Hiroyasu Yokomise.   

Abstract

BACKGROUND: Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme for chromosome segregation during mitosis. Previous experimental studies using cell lines reported that Topo IIalpha expression was negatively regulated by wild-type p53 through the gene's promoter region.
METHODS: Surgically resected tumor specimens from 98 nonsmall cell lung carcinoma (NSCLC) patients who were not treated with preoperative chemotherapy were studied. Quantitative reverse-transcription polymerase chain reaction analysis was done to evaluate Topo IIalpha gene expression. Polymerase chain reaction single strand conformation polymorphism following sequencing was performed to investigate mutations of p53.
RESULTS: Topo IIalpha gene expression in squamous cell carcinomas was significantly higher than in adenocarcinomas (P = 0.0007). Topo IIalpha gene expression in moderately differentiated tumors and poorly differentiated tumors was significantly higher than in well differentiated tumors (P = 0.0032 and P = 0.0005, respectively). Thirty nine tumors (40%) had mutations of p53. Topo IIalpha gene expression in tumors with mutant p53 was significantly higher than in those with wild-type p53 (P = 0.0224).
CONCLUSIONS: The current study suggests that Topo IIalpha gene expression is regulated by p53 gene status in NSCLC patients and that the overexpression of Topo IIalpha induced by mutant p53 might cause more aggressive carcinogenesis. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001123     DOI: 10.1002/cncr.10450

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.

Authors:  Hulya Çelenk Erguden; Deniz Koksal; Funda Demirag; Hulya Bayiz; Neslihan Mutluay; Bahadir Berktas; Mine Berkoglu
Journal:  J Thorac Dis       Date:  2012-08       Impact factor: 2.895

2.  Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC.

Authors:  Meng-Yu Chen; Yue-Can Zeng; Xi-He Zhao
Journal:  Front Cell Dev Biol       Date:  2022-06-15

3.  3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha.

Authors:  Sofia Sagredou; Panagiotis Dalezis; Nikolaos Nikoleousakos; Michail Nikolaou; Maria Voura; Konstantinos Almpanakis; Mihalis I Panayiotidis; Vasiliki Sarli; Dimitrios T Trafalis
Journal:  Onco Targets Ther       Date:  2020-07-28       Impact factor: 4.147

4.  Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance.

Authors:  Chunyu Zhang; Abdel G Elkahloun; Matthew Robertson; Joell J Gills; Junji Tsurutani; Joanna H Shih; Junya Fukuoka; M Christine Hollander; Curtis C Harris; William D Travis; Jin Jen; Phillip A Dennis
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

Review 5.  Topoisomerase IIα in chromosome instability and personalized cancer therapy.

Authors:  T Chen; Y Sun; P Ji; S Kopetz; W Zhang
Journal:  Oncogene       Date:  2014-10-20       Impact factor: 9.867

6.  Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.

Authors:  Guo-Xin Hou; Panpan Liu; Jing Yang; Shijun Wen
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

7.  HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.

Authors:  Michal Stros; Eva Polanská; Sona Struncová; Sárka Pospísilová
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

8.  PTEN stabilizes TOP2A and regulates the DNA decatenation.

Authors:  Xi Kang; Chang Song; Xiao Du; Cong Zhang; Yu Liu; Ling Liang; Jinxue He; Kristy Lamb; Wen H Shen; Yuxin Yin
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

9.  Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.

Authors:  Zahra Fathi; Seyed Ali Javad Mousavi; Raheleh Roudi; Farideh Ghazi
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

10.  Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.

Authors:  Anna Grenda; Justyna Błach; Michał Szczyrek; Paweł Krawczyk; Marcin Nicoś; Barbara Kuźnar Kamińska; Monika Jakimiec; Grażyna Balicka; Izabela Chmielewska; Halina Batura-Gabryel; Marek Sawicki; Janusz Milanowski
Journal:  Cancer Med       Date:  2019-12-03       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.